The revision of the Health Insurance Ordinance (KVV/OAMal) and the Health Benefits Ordinance (KLV/OPAS), presented by the Federal Council in September, will further deteriorate...
RDAF position on the KVV / KLV revision
read more
The RDAF publishes the report from its workshop on post-marketing registries
The report from the RDAF multi-stakeholder workshop on post-marketing registries for rare diseases, which took place on 21 September 2023 in Basel, is now available. The workshop...
RDAF hosts multi-stakeholder workshop on post-marketing registries
The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel,...
RDAF Newsletter
We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year. Highlights include:...
Outcome of the RDAF 2023 General Assembly meeting
The Rare Disease Action Forum (RDAF) held its annual General Assembly meeting on 28 March 2023. During the meeting, the RDAF Secretariat presented an overview of the...
13th International Rare Disease Day in Switzerland
The Rare Disease Action Forum supports the International Rare Disease Day, a globally coordinated movement that advocates for equal access to healthcare, treatments and diagnoses...
The RDAF organizes a webinar on early diagnosis for rare diseases in Switzerland
The Rare Disease Action Forum (RDAF) will host a multi-stakeholder webinar on ‘Early diagnosis for rare diseases’ on 29 March 2023, 17.00-18.30 CET. The webinar focuses on the...
RDAF December 2022 Newsletter
The RDAF is continuously active to raise awareness about rare diseases and improve patients’ access to diagnosis, treatment and care in Switzerland. Below are the highlights of...
Joint statement on the KVV/OAMal and KLV/OPAS revision
The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement...